Primary and latent EBV infection is controlled through a broad array of immune effector pathways which includes neutralizing antibodies, natural killer cells, CD8+ cytotoxic T cells and CD4+ helper T cells directed against multiple EBV antigens52,53. This evidence concerns the gene CD8A and Epstein-Barr virus infection.